These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 18489520)

  • 1. Variable access to clopidogrel in a harmonized EU market.
    Stolk P; Belitser SV; Leufkens HG; Heerdink ER
    Value Health; 2008; 11(5):989-95. PubMed ID: 18489520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Explanations for variations in clopidogrel prescribing in England.
    Petty DR; Silcock J
    J Public Health (Oxf); 2008 Dec; 30(4):494-8. PubMed ID: 18591212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular outcomes after a change in prescription policy for clopidogrel.
    Jackevicius CA; Tu JV; Demers V; Melo M; Cox J; Rinfret S; Kalavrouziotis D; Johansen H; Behlouli H; Newman A; Pilote L
    N Engl J Med; 2008 Oct; 359(17):1802-10. PubMed ID: 18946065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance between clopidogrel use and prescribing guidelines.
    Kubler PA; Pillans PI; Marrinan MC; Frogley M
    Intern Med J; 2004 Dec; 34(12):663-7. PubMed ID: 15610210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
    Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
    Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
    Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
    Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
    Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S;
    J Am Coll Cardiol; 2005 Mar; 45(6):838-45. PubMed ID: 15766816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prior authorization and clopidogrel use--the truth lies in the details.
    Jackson MA; Fairman KA; Curtiss FR
    J Manag Care Pharm; 2009; 15(1):71-7. PubMed ID: 19125553
    [No Abstract]   [Full Text] [Related]  

  • 9. Policy objective of generic medicines from the investment perspective: The case of clopidogrel.
    Elek P; Harsányi A; Zelei T; Csetneki K; Kaló Z
    Health Policy; 2017 May; 121(5):558-565. PubMed ID: 28343810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilisation review of clopidogrel: are they used under the FDA-approved indications?
    Niruntraporn S; Chaiyakunapruk N; Nathisuwan S; Thamlikitkul V
    Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1031-7. PubMed ID: 17551994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why is the use of clopidogrel increasing rapidly in Australia? An exploration of geographical location, age, sex and cardiac stenting rates as possible influences on clopidogrel use.
    Ostini R; Hegney D; Mackson JM; Williamson M; Tett SE
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1077-90. PubMed ID: 18698666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of reducing cardiovascular medication copayments on health spending and resource utilization.
    Choudhry NK; Fischer MA; Avorn JL; Lee JL; Schneeweiss S; Solomon DH; Berman C; Jan S; Lii J; Mahoney JJ; Shrank WH
    J Am Coll Cardiol; 2012 Oct; 60(18):1817-24. PubMed ID: 23040581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic consequences of non-evidence-based clopidogrel use.
    Choudhry NK; Levin R; Avorn J
    Am Heart J; 2008 May; 155(5):904-9. PubMed ID: 18440340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferences on policy options for ensuring the financial sustainability of health care services in the future: results of a stakeholder survey.
    Tordrup D; Angelis A; Kanavos P
    Appl Health Econ Health Policy; 2013 Dec; 11(6):639-52. PubMed ID: 24129648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days.
    von Beckerath N; Kastrati A; Wieczorek A; Pogatsa-Murray G; Sibbing D; Graf I; Schömig A
    Eur Heart J; 2007 Aug; 28(15):1814-9. PubMed ID: 17272357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appropriateness of clopidogrel use according to current recommendations.
    Fornós-Garrigós A; Orozco-Beltrán D; Gil-Guillén VF; Puig-Barberà J; Fluixa C; Fernández A
    Fam Pract; 2014 Dec; 31(6):694-8. PubMed ID: 25114161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.
    Calver AL; Blows LJ; Harmer S; Dawkins KD; Gray HH; Morgan JH; Simpson IA
    Am Heart J; 2000 Sep; 140(3):483-91. PubMed ID: 10966552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey.
    Davies A; Bakhai A; Schmitt C; Barrett A; Graham-Clarke P; Sculpher M
    J Med Econ; 2013; 16(4):510-21. PubMed ID: 23339464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction.
    Gibler KB; Huskamp HA; Sabatine MS; Murphy SA; Cohen DJ; Cannon CP
    Crit Pathw Cardiol; 2010 Mar; 9(1):14-8. PubMed ID: 20215905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
    Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
    Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.